Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
October 2023 Community Statement from Novartis
“The CMTA welcomes this community update from Novartis and applauds its leading role in the development of treatments for CMT. The CMTA has been maintaining regular contact, providing support and…
CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO
…treatments for rare diseases, will take the helm of the patient-led nonprofit as it moves to the next phase of its search for a cure for CMT. Dr. Bruhn brings…
Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003
…can be influenced by placebo and training effects, making it difficult to determine the impact of treatment. In particular, the company said, the Overall Neuropathy Limitation Scale (ONLS), which measures…
CMTA and Applied Therapeutics Announce Collaboration for CMT-SORD
…Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of…
CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B
…CMTA’s global leadership in accelerating innovative research to bring treatments to CMT. Led by John Svaren, PhD, at the University of Wisconsin, this research is part of a larger initiative…
Bruce R Conklin, MD Joins the CMTA STAR Advisory Board
…use these model cells to test the effects of the CRISPR gene editing treatments they are developing. If the treatment is found to be effective in the human model cells,…
Coronavirus (COVID-19) Update
…COVID-19 has now been detected in 60 locations internationally, including in the United States. The resources below provide information about the virus, how it spreads, symptoms, prevention/treatment and more. Please…
CMTA Event Schedule Update from CEO Amy Gray
…prevention/treatment and more. We ask you to review the information contained in these links to be better informed about the coronavirus. CDC: Prevention & Treatment World Health Organization: Coronavirus Disease…
New Gene Therapy Development Program for CMT2A
Philadelphia, PA – September 9, 2019 – Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced…
CMTA-STAR Biotech & Alliance Partners
…endpoints to track treatment effects to be used in a planned gene therapy trial. Read more Frontage Laboratories Frontage Laboratories, Inc. is a global pharmaceutical development organization (PDO) advancing drug…